Continuous Manufacturing Adoption in Pharma and the Reagents It Shifts Demand For

Continuous manufacturing is increasingly adopted in pharma to improve efficiency, reduce waste and shorten time‑to‑market. It drives higher demand for high‑purity solvents, specialised catalysts, real‑time analytical reagents and robust excipients that meet tighter quality and regulatory specifications.

How is continuous manufacturing being adopted in the pharmaceutical industry?

The US Food and Drug Administration (FDA) released a guidance document in 2020 encouraging the use of continuous processes for both drug substances and drug products, citing potential reductions in manufacturing cycle time of up to 30 % and a 20‑40 % decrease in material waste[^1]. The European Medicines Agency (EMA) followed with a similar guideline in 2021, highlighting that more than 15 % of new drug applications now propose at least one continuous step[^2]. Major companies such as Pfizer, Novartis and Merck have reported pilot lines for continuous flow synthesis of active pharmaceutical ingredients (APIs) and continuous tablet press lines, with commercial scale roll‑outs expected by 2025. McKinsey estimates that by 2030 continuous manufacturing could account for 25‑30 % of global pharma output, representing a $15 bn market shift[^3].

Which reagents see increased demand with continuous manufacturing?

Continuous processes require reagents that can be introduced and removed without interrupting flow. The most notable shifts are:

• High‑purity solvents – Solvents such as anhydrous acetonitrile, methanol and dimethylformamide (DMF) must meet USP or EP specifications at >99.9 % purity to avoid fouling reactors and downstream separators.
• Specialised catalysts – Homogeneous catalysts (e.g., palladium‑based cross‑coupling systems) are preferred for their rapid turnover and ease of removal via inline scavenging. Heterogeneous catalysts on polymer‑supported beads are also gaining traction for continuous hydrogenation.
• Real‑time analytical reagents – Inline HPLC, GC‑MS and NMR probes rely on calibrated standards (e.g., deuterated solvents for NMR, internal standards for HPLC) to provide Process Analytical Technology (PAT) data required by FDA and EMA.
• Robust excipients – For continuous tablet compression, excipients such as microcrystalline cellulose, mannitol and magnesium stearate must exhibit narrow particle‑size distributions (often Dv90 < 150 µm) to ensure consistent flow and compression.
• Stabilisers and buffers – Continuous bioprocessing of biologics uses high‑grade HEPES, Tris and PBS buffers, often supplied with low endotoxin levels (<0.1 EU/mL) to meet GMP standards.

These reagents are typically sourced in bulk, with suppliers offering on‑demand logistics to match the reduced inventory footprints of continuous lines.

What impact does continuous manufacturing have on reagent specifications and quality standards?

Regulatory frameworks such as GHS, REACH and TSCA remain applicable, but continuous manufacturing adds layers of specification:

• Lot‑to‑lot consistency – Because a single lot may be used for weeks of uninterrupted production, manufacturers demand tighter impurity limits (often <0.05 % vs. the usual <0.1 %).
• Stability under flow conditions – Reagents must withstand elevated temperatures (often 80‑120 °C) and pressures (up to 30 bar) without degradation. Suppliers therefore provide data sheets with thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC) results.
• Traceability and CoA – Continuous processes rely on real‑time monitoring; any deviation triggers an immediate batch hold. Consequently, full Certificates of Analysis (CoA) and SDS are required for each delivery, with electronic access to batch records.
• Compatibility with PAT – Reagents used in inline spectroscopic methods must be free of interfering chromophores. For example, deuterated solvents for NMR must have <0.5 % residual proton content to avoid baseline distortion.

Molekula, as a specialist supplier, provides high‑purity grades that meet USP‑NF and EP specifications, with optional on‑site analytical support to verify compliance before release.

How do regulatory frameworks influence reagent selection for continuous processes?

Both the FDA and EMA require that any material introduced into a continuous line be justified in the regulatory submission. The FDA’s PAT framework mandates that critical quality attributes (CQAs) be monitored in real time, meaning that reagents must be accompanied by validated analytical methods and stability data[^1][^2]. REACH registration remains mandatory for all chemicals placed on the EU market, but the continuous model can reduce the total number of distinct chemicals used, simplifying compliance.

In the United States, the Toxic Substances Control Act (TSCA) obliges manufacturers to disclose any new chemical entities above 10 t/yr. Continuous processes often replace batch‑specific reagents with universal solvents, thereby lowering the number of TSCA‑listed substances. Conversely, the need for high‑purity grades can trigger additional ISO 9001 or ISO 13485 audits for suppliers, especially when reagents are used in sterile biologic manufacturing.

Overall, regulatory scrutiny pushes suppliers to provide detailed SDS, batch‑specific CoA, and, where required, GMP‑certified documentation. This drives a market shift toward suppliers that can guarantee traceability and rapid delivery.

What operational challenges arise when sourcing reagents for continuous manufacturing?

While the demand for specialised reagents is clear, several practical issues persist:

• Supply‑chain synchronisation – Continuous lines operate 24/7; any delay in reagent delivery can halt production. Companies are therefore adopting just‑in‑time (JIT) contracts with multiple qualified vendors.
• Scale‑up validation – Reagents that perform well at pilot scale may exhibit different solubility or viscosity at commercial flow rates. Suppliers often provide scale‑up data sheets to mitigate this risk.
• Waste handling – Continuous processes generate smaller but more constant streams of waste solvent. Reagents with built‑in recyclability (e.g., recoverable ionic liquids) are gaining interest.
• Cost considerations – High‑purity grades command premium prices (often 1.5‑2× the standard bulk price). However, the overall cost of ownership can be lower due to reduced batch failures and waste.

Addressing these challenges requires close collaboration between pharma engineers, quality assurance teams and reagent suppliers. Molekula’s technical service team can assist with custom packaging, stability testing and regulatory documentation to streamline integration.

Sources

Sources

[^1]: FDA. Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry. 2020. https://www.fda.gov/media/124792/download [^2]: EMA. Guideline on continuous manufacturing of medicinal products. 2021. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-continuous-manufacturing-medicinal-products_en.pdf [^3]: McKinsey & Company. The Future of Pharmaceutical Manufacturing. 2022. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-future-of-pharma-manufacturing [^4]: ACS Publications. Continuous flow chemistry in API production. 2021. https://pubs.acs.org/doi/10.1021/acs.oprd.1c00123 [^5]: European Chemicals Agency. REACH and continuous manufacturing: implications for chemical suppliers. 2020. https://echa.europa.eu/documents/10162/245678/reach_continuous_manufacturing.pdf

Frequently asked questions

Q1: Does continuous manufacturing require different grades of solvents compared with batch processes? A: Yes, continuous lines typically demand solvents of ≥99.9 % purity (USP/EP grade) to prevent fouling and maintain consistent reaction kinetics.

Q2: How does PAT affect the choice of analytical reagents? A: PAT mandates real‑time data; therefore, reagents must be compatible with inline HPLC, NMR or GC‑MS probes and supplied with validated reference standards.

Q3: Are there cost benefits to sourcing high‑purity reagents for continuous manufacturing? A: Although unit costs are higher (often 1.5‑2×), overall manufacturing costs can fall due to reduced batch failures, lower waste and shorter cycle times.

Q4: What regulatory documents must accompany reagents for continuous bioprocessing? A: Suppliers must provide an up‑to‑date SDS, full CoA, and, where applicable, GMP‑certified documentation to satisfy FDA, EMA and REACH requirements.